IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qua... ( IRVINE Calif. April 3 /- IDM Pharma I...)

HOME >> MEDICINE >> NEWS

IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification

Date:4/3/2009

IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI), a company focused on the development of innovative cancer products, including MEPACT(R) (known as mifamurtide in the United States), which was recently approved in Europe for the treatment of osteosarcoma, today announced that its financial statements for the fiscal year ended December 31, 2008, included in the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2009, contain a going concern qualification from its independent registered public accounting firm.

This announcement is being made in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of a recent audit opinion that contains a going concern qualification.

As previously announced, the company is currently evaluating available strategic alternatives. The options the company is considering include various strategic transactions, including merger or acquisition opportunities, which may involve a change in control of the company. The company has engaged JMP Securities, an investment bank, to advise it in exploring alternatives available with respect to a possible merger or acquisition transaction.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit www.idm-pharma.com.

'/>"/>

SOURCE IDM Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
2. SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor
3. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
4. CVS Caremark Announces Results of Annual Employer Survey Validating Proactive Pharmacy Care Approach
5. Actress and Mom Alison Sweeney Teams Up With the American Pharmacists Association to Help Fellow Allergy Sufferers Find Relief This Spring
6. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
7. Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical
10. State Budget Preserves State Pharmacy Program for Seniors (EPIC)
11. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer

Post Your Comments:

(Date:5/20/2013)... (PRWEB) May 20, 2013 Medicare Part ... overwhelmingly satisfied, citing lower costs, convenient access to pharmacies ... Hart Research Associates released today by the Pharmaceutical Care ... seniors (9.5 million) are currently enrolled in plans with ... choices, and overall value of plans with preferred pharmacy ...

(Date:5/20/2013)... 2013 Today, Allayo announced the debut ... A mobile application called Allie helps health care consumers ... takes to arrange for quality health care. Ideal for ... of mobile technology and access to personalized service from ... their health care needs are being met. Allie is ...

(Date:5/20/2013)... Cliff Lake Dental Care is pleased to announce ... when visiting the dentist office . The change was made ... , Here are the new office hours: Mondays- 8 a.m. to ... a.m. to 1 p.m. and 2-5 p.m., Thursdays 7 a.m. to ... be open to take appointments only. Cliff Lake Dental wants to ...

(Date:5/20/2013)... improved health care and significant reductions in drug costs ... between physicians and drug company representatives who promote the ... This system, which has been in place for decades, ... to date on new medications, and always provided generous ... the newest drugs, as well as other supplies and ...

(Date:5/20/2013)... (PRWEB) May 20, 2013 A ... Business Intelligence solutions, i2i Systems announced ... Award-winning Southcentral Foundation (SCF) selected i2iTracks as their ... help them meet their Meaningful Use (MU), Government ... System (UDS) requirements – a welcomed solution to ...

Breaking Medicine News(10 mins):Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2 Health News:Allayo Debuts Virtual Health Assistant At HealthBeat 2013 2 Health News:Cliff Lake Dental Care Announces Office Hours Change 2 Health News:Breakup of physician, drug company relationship could improve health care, cut cost 2 Health News:Breakup of physician, drug company relationship could improve health care, cut cost 3 Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 2 Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 3

[0] Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices [0] Allayo Debuts Virtual Health Assistant At HealthBeat 2013 [0] Cliff Lake Dental Care Announces Office Hours Change [0] Breakup of physician, drug company relationship could improve health care, cut cost [0] Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements

... most common breast cancer uses the most efficient, powerful ... that system kills it, researchers report. This method ... patients, particularly those resistant to standard therapies such as ... Human estrogen receptor-positive breast cancer cells thriving in a ...

... The second generation drug-eluting stent, everolimus-eluting stent ... in randomised controlled trials over the first ... earlier studies comparing EES with another first ... only demonstrated the non-inferiority of EES; the ...

... order to meet future demands for new pharmaceuticals, ... is dependent on the ongoing development of effective ... Because they are so versatile, organometallic molecules are ... reagents containing zinc atoms have certain advantages over ...

... , MONDAY, Aug. 29 (HealthDay News) -- Boxing ... encourage their kids to find sports that don,t focus ... Those are conclusions from the new policy statement from ... Society that recommends that pediatricians vigorously oppose children participating ...

... Meeting & OTO EXPO of the American Academy of Otolaryngology ... of ear, nose, and throat doctors in the world, will ... more than 386 scientific research sessions, 468 posters, and several ... a unique opportunity for journalists from around the world to ...

... 28 (HealthDay News) -- Although it may sound sweet ... behavior, similar to arguing or slinging insults, Canadian scientists ... Queens University in Kingston, Ontario, also revealed that differences ... live, play a role in how aggressive their shouting ...

Research aims to starve breast cancer cells Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents New salts for chemical soups Pediatric Groups Want to KO Boxing for Kids 2011 AAO-HNSF poster presentations Sweet Sparrow Songs May Actually Be Shouting Matches

(Date:5/19/2013)... May 20, 2013 Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...

(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...

(Date:5/17/2013)... , May 17, 2013 Sorrento Therapeutics, ... its Fast-Track Advanced Technology Small Business Technology Transfer ... of Allergy and Infectious Diseases (NIAID), a division ... the development of novel human antibody therapeutics to ... or Staph) infections, including methicillin-resistant S. ...

Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4 Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4

[0] Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak [0] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm [0] Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases

... today reported one year,survival results from a Phase I/II ... in combination with dacarbazine in,patients with unresectable stage III ... cohort of patients in both the Phase I and,Phase ... the entire patient,set and a 22 month overall mean ...

... (NYSE:,AZN) today announced that the company has submitted ... U.S. Food and Drug,Administration (FDA) for once-daily SEROQUEL ... the treatment of manic,episodes associated with bipolar disorder ... disorder., The bipolar mania submission is based ...

Cached Medicine Technology:AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 2 AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 3 AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 4 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 2 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 3 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 4 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 5 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 6 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 7

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression

... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...

... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...

... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...

... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...

Medicine Products:

Alligator Micro-Grasper Atraumatic Grasper Reddick Grasper Long Dolphin Nose Grasper